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Abstract
Background. Substance use disorder explains much of the excess risk of violent behaviour in
psychotic disorders. However, it is unclear to what extent the pharmacological properties and
subthreshold use of illicit substances are associated with violence.
Methods. Individuals with psychotic disorders were recruited for two nationwide projects:
GROUP (N = 871) in the Netherlands and NEDEN (N = 921) in the United Kingdom.
Substance use and violent behaviour were assessed with standardized instruments and mul-
tiple sources of information. First, we used logistic regression models to estimate the associa-
tions of daily and nondaily use with violence for cannabis, stimulants, depressants and
hallucinogens in the GROUP and NEDEN samples separately. Adjustments were made for
age, sex and educational level. We then combined the results in random-effects meta-analyses.
Results. Daily use, compared with nondaily or no use, and nondaily use, compared with no
use, increased the pooled odds of violence in people with psychotic disorders for all substance
categories. The increases were significant for daily use of cannabis [pooled odds ratio (pOR)
1.6, 95% confidence interval (CI) 1.2–2.0), stimulants (pOR 2.8, 95% CI 1.7–4.5) and depres-
sants (pOR 2.2, 95% CI 1.1–4.5), and nondaily use of stimulants (pOR 1.6, 95% CI 1.2–2.0)
and hallucinogens (pOR 1.5, 95% CI 1.1–2.1). Daily use of hallucinogens, which could only be
analysed in the NEDEN sample, significantly increased the risk of violence (adjusted odds
ratio 3.3, 95% CI 1.2–9.3).
Conclusions. Strategies to prevent violent behaviour in psychotic disorders should target any
substance use.
Introduction
Much of the excess risk of violent behaviour in psychotic disorders can be explained by sub-
stance use disorder (SUD) (Fazel et al., 2009). In a meta-analysis of 16 studies with a total of
5365 cases, SUD more than doubled the odds of violence [odds ratio (OR) 2.2, 95% confidence
interval (CI) 1.6–2.9] (Witt et al., 2013).
However, it is unclear to what extent different categories of illicit substances, as defined by
their psychopharmacological effects, are related to violent behaviour. Another uncertainty is
whether subthreshold use, as opposed to SUD, is a risk factor for violence. These questions
may be clinically relevant, as the psychopharmacological properties of substances modify
violence risk in the general population (Tomlinson et al., 2016) and people with psychotic dis-
orders are highly sensitive to the harmful effects of substances (Gregg et al., 2007). The few
studies of cannabis (Koen et al., 2004; Moulin et al., 2018; Oluwoye et al., 2019) and stimulants
(Bell et al., 2002; Miles et al., 2003; Harris et al., 2010) have produced conflicting results.
Moreover, these studies have been limited by small samples of inpatients and proxy measures
of violent behaviour (e.g. hostility, aggression). A recent meta-analysis of 12 studies involving
3873 subjects with severe mental illness – but not psychotic disorders specifically – reported
a significant association between cannabis use and violence [pooled odds ratio (pOR) 3.0,
95% CI 2.0–4.5] (Dellazizzo et al., 2019). To our knowledge, there have been no studies of
depressants (besides alcohol) or hallucinogens.
To address the limitations of previous studies, we have investigated the associations of daily
and nondaily use with violent behaviour for cannabis, stimulants, depressants and hallucino-
gens in two nationwide samples of individuals with psychotic disorders.
Methods
We used baseline data from two research projects: Genetic Risk and Outcome of Psychosis
(GROUP) (Korver et al., 2012) and National Evaluation of the Development and Impact of
Early Intervention Services (NEDEN) (Birchwood et al., 2014).
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Setting and participants
GROUP
GROUP is conducted by four university medical centres (i.e.
Amsterdam Medical Centre, Maastricht University Medical
Centre+, University Medical Centre Groningen, University
Medical Centre Utrecht) and affiliated mental health centres
(k = 36) in the Netherlands. These centres are located in geo-
graphically representative areas of the country and provide access
to treatment in a variety of settings (e.g. psychiatric hospitals, out-
patient clinics) to approximately 75% of the population.
Recruitment took place in 2004. To be eligible for participation,
patients had to (i) be aged between 16 and 50, (ii) have a good
command of the Dutch language and (iii) meet Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, Text
Revision (DSM-IV-TR) (American Psychiatric Association,
2000) criteria for schizophrenia or another psychotic disorder.
In accordance with standard local practice, DSM-IV-TR diagno-
ses were made with the Comprehensive Assessment of
Symptoms and History (Andreasen et al., 1992) or Schedules
for Clinical Assessment for Neuropsychiatry (Wing et al., 1990).
NEDEN
All individuals enrolled into Early Intervention Services (EIS) at
five sites across England (i.e. Birmingham, Cornwall,
Cambridge, Norwich, Lancashire) between 2005 and 2009 were
invited to participate. Sites were chosen to reflect urban and
rural differences. The Department of Health and Social Care
requires that people receiving EIS are between 14 and 35 years
old and present with a first episode of psychosis. No additional
inclusion criteria were set. The Operationalized Criteria System
(McGuffin et al., 1991) was used to determine International
Statistical Classification of Diseases and Related Health
Problems, Tenth Edition (ICD-10) (World Health Organization
[WHO], 1992) diagnoses of mental disorders.
Measures
Information about the instruments’ psychometric properties can
be found in the relevant publications for GROUP (Korver et al.,
2012) and NEDEN (Birchwood et al., 2014). Unless otherwise
specified, the reference period was the lifetime.
GROUP
Substance use: The Substance Abuse Module of the Composite
International Diagnostic Interview (CIDI-SAM) (WHO, 1990)
was used to measure the frequency (i.e. daily use, nondaily use,
no use) and severity (i.e. problematic use, nonproblematic use,
no use) of substance use. The CIDI-SAM distinguishes between
the following categories of substances: (i) alcohol; (ii) cannabis;
(iii) cocaine; (iv) stimulants (e.g. amphetamine, khat); (v) seda-
tives (e.g. pentobarbital, diazepam); (vi) opiates (e.g. heroin,
codeine); (vii) inhalants (e.g. toluene, butane); (viii) phencyclidine
(PCP); (ix) psychedelics [e.g. lysergic acid diethylamide (LSD),
mescaline]; and (x) other substances [e.g. amyl nitrite,
3,4-methylenedioxymethamphetamine (MDMA)]. Based on con-
siderations of statistical power and similarities in psychophar-
macological effects, we combined cocaine and stimulants as
‘stimulants’, sedatives, opiates and inhalants as ‘depressants’ and
PCP and psychedelics as ‘hallucinogens’ (cf. Hill and Thomas,
2016). Cannabis, which has stimulant, depressive and hallucino-
genic properties, was treated separately owing to the high
prevalence of its use. We defined problematic alcohol use as an
average intake of more than 18 standard drinks per week for
men and more than 12 standard drinks per week for women dur-
ing a minimum period of 2 weeks in the past year or 4 weeks at any
other point in the past. These cutoffs reflect the median of several
national guidelines and a consistent 1.5:1 male to female consump-
tion ratio (Furtwaengler and de Visser, 2013). For other substances,
problematic use corresponded to a DSM-IV-TR diagnosis of abuse
or dependence.
Violent behaviour: Violent behaviour was established with the
Life Chart Schedule (LCS) (Susser et al., 2000). Designed to
record the development of symptoms, health care consumption
and social functioning in schizophrenia patients, the LCS contains
the following question regarding violence: ‘Did the patient phys-
ically attack or abuse someone else?’ The LCS was filled out based
on review of clinical case notes and interviews with the patient
and, if possible, one or both parents.
NEDEN
Substance use: A purposely designed questionnaire was used to
assess substance use. For 15 substance categories, patients were
asked whether they had used them: (i) almost every day; (ii) 1
to 3 times per week; (iii) less than once per week; (iv) 3 times
or less; or (v) never. For the sake of consistency, we combined fre-
quency categories ii, iii and iv as ‘nondaily use’ and refer to
‘almost every day’ as ‘daily’. The substance categories were rear-
ranged as follows: (i) cannabis; (ii) stimulants (i.e. cocaine,
amphetamine, khat); (iii) depressants (i.e. opiates,
γ-hydroxybutyric acid, barbiturates, benzodiazepines, solvents,
‘poppers’); (iv) hallucinogens (i.e. LSD, psilocybin, ketamine);
and (v) other substances (i.e. MDMA, ‘other’) (cf. Hill and
Thomas, 2016).
Violent behaviour: Violent behaviour was ascertained from
patient and clinician interviews using the Adverse Outcomes
Questionnaire (AOQ). In the AOQ, a shortened version of the
questionnaire used in the MacArthur Violence Risk Assessment
Study (Steadman et al., 1998), violence is operationalized to
encompass: (i) battery that resulted in physical injury; (ii) sexual
assault; (iii) assault involving the use of a weapon; (iv) threats
made with a weapon in hand; and (v) battery that did not result
in physical injury. The AOQ referred to the past 12 months.
Analyses
First, we used logistic regression models to estimate the
associations of daily and nondaily use with violent behaviour
for cannabis, stimulants, depressants and hallucinogens in the
GROUP and NEDEN samples separately. Three comparisons
were made: (i) daily use v. nondaily or no use; (ii) daily use v.
no use; and (iii) nondaily use v. no use. For theoretical reasons,
we included the confounders age, sex and educational level
(Lamsma and Harte, 2015). Educational level, indicating whether
a patient had completed secondary school, served as a proxy for
socioeconomic status (Maksimović et al., 2008). We only analysed
complete cases. Depending on the scale of measurement, com-
plete and incomplete cases were compared on each model variable
with the χ2-test (dichotomous) or t test (continuous). To improve
validity, we required models with at least 5 observations per cell in
the 2 × 2 table of the exposure and outcome of interest.
We then combined the results for the GROUP and NEDEN
samples in random-effects meta-analyses. The I2 statistic was
used as a measure of heterogeneity. Values of 25, 50 and 75%
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denoted low, moderate and high levels of heterogeneity, respect-
ively (Higgins et al., 2003).
For sensitivity analyses, we examined severity of use. Alcohol,
which has consistently been found to increase violence risk in
people with psychotic disorders (Witt et al., 2013), was used as
a positive control.
The level of statistical significance was set at 5%. Analyses were
carried out in STATA 12.1.
Results
Of the 1013 patients in the GROUP sample, 871 (86%) had data
on all model variables and were thus included in the analyses. The
corresponding numbers in the NEDEN sample were 1027 and
921 (90%), respectively. Complete cases differed significantly
from incomplete cases on age [t(1011) = 3.31, p = 0.001] in the
GROUP sample (online Supplementary Table S1) and educa-
tional level [χ2 (1) = 3.89, p = 0.049] in the NEDEN sample
(online Supplementary Table S2).
Demographic and clinical characteristics of patients
GROUP
Demographic and clinical characteristics of the patients (N = 871)
are presented in Table 1. The mean age was 27.3 years (S.D. = 7.1).
Most patients were male (n = 673, 77%) and had received a diag-
nosis of schizophrenia (n = 602, 69%). Use of illicit substances was
reported by 602 (69%) patients. About one if five patients had
been violent (n = 179, 21%).
NEDEN
The patients (N = 921) had a mean age of 22.8 years (S.D. = 4.8)
and were predominantly male (n = 639, 69%). (Table 1). The
most common diagnosis was schizophrenia (n = 478, 47%).
Almost two thirds of the patients had used illicit substances
(n = 589, 64%). The prevalence of violent behaviour was 22%
(n = 204).
Primary analyses
GROUP
Daily use, compared with nondaily or no use, and nondaily use
increased the adjusted odds of violent behaviour for all substance
categories (Table 2). The increases were significant for daily use of
stimulants [adjusted odds ratio (aOR) 2.2, 95% CI 1.3–3.8] and
nondaily use of hallucinogens (aOR 1.8, 95% CI 1.2–2.7).
NEDEN
When comparing daily use with nondaily or no use, cannabis
(aOR 1.8, 95% CI 1.3–2.5), stimulants (aOR 3.6, 95% CI 2.1–
6.4), depressants (aOR 3.3, 95% CI 1.5–7.2) and hallucinogens
(aOR 3.3, 95% CI 1.2–9.3) significantly increased the adjusted
odds of violence (Table 2). Nondaily use increased the aORs for
these substance categories as well, with that for stimulants reach-
ing statistical significance (aOR 1.6, 95% CI 1.2–2.3).
Meta-analyses
Pooled across the GROUP and NEDEN samples, daily use of can-
nabis (pOR 1.6, 95% CI 1.2–2.0), stimulants (pOR 2.8, 95% CI
1.7–4.5) and depressants (pOR 2.2, 95% CI 1.1–4.5) significantly
increased the odds of violence compared with nondaily or no use
(Table 3). The same was found for nondaily use (compared with
no use) of stimulants (pOR 1.6, 95% CI 1.2–2.0) and hallucino-
gens (pOR 1.5, 95% CI 1.1–2.1). Moderate heterogeneity was pre-
sent for daily use of depressants in both comparisons (I2 = 46%,
50%). Otherwise, heterogeneity was low (I2⩽ 36%).
Sensitivity analyses
We observed no material differences in results after repeating the
analyses in the GROUP sample with severity of use. As expected,
alcohol increased the adjusted odds of violence (online
Supplementary Table S3).
Discussion
In two nationwide samples totalling 1792 individuals with psych-
otic disorders, we investigated associations between frequency of
use and violence for different categories of illicit substances.
Table 1. Demographic and clinical characteristics of patients in the GROUP
(N = 871) and NEDEN (N = 921) samples
GROUP NEDEN
Demographic characteristics
Age, mean (S.D.) in years 27.3 (7.1) 22.8 (4.8)
Male 673 (77) 639 (69)
Caucasian 679 (79) 679 (74)
Completed secondary school 753 (86) 811 (88)
Clinical characteristics
Psychiatric diagnosisa
Schizophrenia 602 (69) 478 (47)
Schizoaffective disorder 106 (12) 70 (7)
Psychotic disorder NOS 74 (8) 190 (19)
Other 89 (10) 289 (28)
Age of onset, mean (S.D.) in years 23.1 (6.5) 21.3 (4.9)
Use of illicit substances
Daily 430 (49) 314 (34)
Cannabis 411 (48) 285 (31)
Stimulants 68 (8) 55 (6)
Depressants 51 (6) 28 (3)
Hallucinogens 6 (1) 15 (2)
Other 23 (3) 21 (2)
Nondaily 427 (49) 480 (52)
Cannabis 170 (20) 279 (30)
Stimulants 198 (24) 245 (27)
Depressants 62 (8) 89 (10)
Hallucinogens 165 (20) 161 (17)
Other 212 (26) 230 (25)
Violent behaviour 179 (21) 204 (22)
S.D., standard deviation; NOS, not otherwise specified.
Data are n (%), unless otherwise stated.
aPsychiatric diagnoses were only available for the full NEDEN sample (N = 1027).
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Overall, daily and nondaily use of cannabis, stimulants, depres-
sants, and hallucinogens were found to increase violence risk.
There are at least four ways in which substance use may lead to
violent behaviour in psychotic disorders. First, psychopharmaco-
logical effects of intoxication with or withdrawal from substances
(e.g. disinhibition, intensification of negative emotions) may
lower the threshold for violence (Kuhns and Clodfelter, 2009).
Substance use may also induce or exacerbate positive symptoms
(e.g. delusions, hallucinations) (Winklbaur et al., 2006), which
are risk factors for violent behaviour (Witt et al., 2013). This
may be particularly relevant for cannabis and hallucinogens.
The former has been found to increase the risk of developing a
psychotic disorder (Di Forti et al., 2019), and the latter – with
the possible exception of PCP – are thought not to increase vio-
lence risk in the general population (Tomlinson et al., 2016).
Second, substance use may interfere with treatment. Individuals
with problematic substance use are less likely to seek and adhere
to treatment than those without these substance problems
(Winklbaur et al., 2006). At the same time, substances may be
used in an attempt to alleviate psychotic symptoms or unpleasant
side effects of antipsychotics (Gregg et al., 2007). Self-medication
increases the likelihood of avoidance or discontinuation of treat-
ment and vice versa (Swartz et al., 1998). Substances may also
reduce the therapeutic activity of antipsychotics (Lindsey et al.,
2012). In the absence of effective treatment, positive symptoms
may persist or worsen. Third, violence may occur during the com-
mission of crimes to gain access to substances or the money to
buy them (McGinty et al., 2016). Finally, users may become
involved in illegal drug markets where violent behaviour is com-
monplace (Hodgins, 2008). Other explanations for the findings
are confounding or mediation by biological (e.g. genetics, neuro-
biological abnormalities), psychological (e.g. cognitive impair-
ment, personality pathology) or environmental (e.g. childhood
maltreatment, erosion of social support) risk factors (Lamsma
and Harte, 2015).
As far as we know, this is the largest study to investigate the
relationship between use of illicit substances and violent behav-
iour in psychotic disorders. It has several strengths. First, the sam-
ples were drawn from diverse geographic areas and care settings.
Sampling was also independent of the exposures and outcome of
interest. This enhanced the generalizability of the results. Second,
the use of multiple data sources increased the sensitivity of the
LCS and AOQ as measures of violence. Finally, the findings for
alcohol (as a positive control) were in the expected direction, sup-
porting the validity of the design. However, there are several lim-
itations. First, causality cannot be inferred, as the temporal
relationship between substance use and violent behaviour was
not known and we did not control for other confounders besides
age, sex and educational level. Second, we included individuals
who had used substances belonging to different categories,
which may have biased risk estimates. Exclusion would have
made cell counts too low for meaningful analyses of most sub-
stance categories. Third, daily use was a proxy measure of SUD.
However, similar results were obtained for DSM-IV-TR diagnoses
Table 2. Prevalence and risk of violent behaviour by different categories of illicit substances and frequency of their use in the GROUP (N = 871) and NEDEN (N = 921)
samples
n (%) aOR (95% CI)a
Substance category DU NDU NU DU v. NDU or NU DU v. NU NDU v. NU
GROUP
Cannabis 99 (24) 36 (21) 44 (15) 1.4 (1.0–1.9) 1.5 (1.0–2.3) 1.3 (0.8–2.2)
Stimulants 25 (37) 48 (24) 98 (17) 2.2 (1.3–3.8) 2.6 (1.5–4.5) 1.5 (1.0–2.2)
Depressants 15 (29) 18 (29) 134 (19) 1.6 (0.9–3.1) 1.7 (0.9–3.3) 1.7 (0.9–3.0)
Hallucinogens 3 (50) 46 (28) 113 (17) – – 1.8 (1.2–2.7)
Other 8 (35) 57 (27) 100 (17) 1.9 (0.8–4.6) 2.4 (1.0–5.8) 1.7 (1.2–2.6)
NEDEN
Cannabis 88 (30) 60 (21) 61 (17) 1.8 (1.3–2.5) 2.0 (1.3–2.9) 1.2 (0.8–1.8)
Stimulants 26 (46) 71 (28) 112 (17) 3.6 (2.1–6.4) 4.3 (2.4–7.8) 1.6 (1.2–2.3)
Depressants 13 (43) 23 (26) 173 (21) 3.3 (1.5–7.2) 3.4 (1.6–7.3) 1.2 (0.7–2.0)
Hallucinogens 7 (47) 44 (27) 158 (21) 3.3 (1.2–9.3) 3.4 (1.2–9.6) 1.3 (0.9–1.9)
Other 10 (45) 65 (27) 134 (19) 3.4 (1.4–8.2) 3.9 (1.6–9.3) 1.5 (1.0–2.1)
aOR, adjusted odds ratio; CI, confidence interval; DU, daily use; NDU, nondaily use; NU, no use.
Due to missing data, the total number of patients varies by substance category.
aAdjusted for age, sex and educational level.
Table 3. Risk of violent behaviour by different categories of illicit substances
and frequency of their use, pooled across the GROUP (N = 871) and NEDEN
(N = 921) samples
pOR (95% CI)
Substance
category
DU v. NDU or
NU DU v. NU NDU v. NU
Cannabis 1.6 (1.2–2.0) 1.7 (1.3–2.3) 1.2 (0.9–1.7)
Stimulants 2.8 (1.7–4.5) 3.3 (2.0–5.4) 1.6 (1.2–2.0)
Depressants 2.2 (1.1–4.5) 2.3 (1.2–4.6) 1.4 (0.9–2.1)
Hallucinogens – – 1.5 (1.1–2.1)
Other 2.5 (1.4–4.7) 3.1 (1.6–5.7) 1.6 (1.2–2.1)
pOR, pooled odds ratio; CI, confidence interval; DU, daily use; NDU, nondaily use; NU, no use
(using random-effects models).
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of abuse and dependence in the GROUP sample. Fourth, the def-
inition and reference period for violence varied between GROUP
and NEDEN. The more stringent definition and shorter reference
period may explain why aORs were slightly higher in the NEDEN
sample. Fifth, missing data may have limited the validity of the
results. Sixth, the results of the meta-analyses should be treated
with some caution: the estimation of the between-study variance,
which is used in the calculation of the pooled effect size and its
confidence interval, may be inaccurate when the number of stud-
ies is small (Borenstein et al., 2009). Seventh, we were unable to
analyse PCP separately. Either too few patients had used PCP
(GROUP) or no specific information was recorded for PCP
(NEDEN). Finally, there has been a large increase in the use of
novel psychoactive substances (NPS) in the years following data
collection (Tracy et al., 2017). NPS are synthetic compounds
designed to mimic the psychopharmacological effects of trad-
itional substances (Miliano et al., 2016). Therefore, we hypothe-
size that NPS increase violence risk.
A clinical implication of the findings is that violence risk
assessment in psychotic disorders should target any substance
use. For structured instruments, it should be determined whether
items for SUD and subthreshold use of different substance cat-
egories have incremental validity over a single item for SUD.
The findings also suggest that interventions, which currently
focus on SUD, may assist in the prevention of violent behaviour
in patients with subthreshold use (Chang et al., 2016). To clarify
causal mechanisms, we recommend that studies further isolate the
psychopharmacological effects of substances, use prospective
designs and test for additional confounders and mediators.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291719002125.
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